Sab Biotherapeutics Inc (SABS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 263 | 945 | 305 | 1,267 | 86 |
| Gross Profit | 263 | 945 | 305 | 1,267 | 86 |
| Operating Expenses | 10,465 | 12,335 | 19,179 | 6,590 | 6,562 |
| Operating Income | -10,202 | -11,391 | -18,874 | -5,323 | -6,477 |
| Interest Expense | 93 | 76 | 78 | 70 | 75 |
| Other Income | 2,959 | 6,441 | -3,905 | 290 | -329 |
| Pre-tax Income | -7,336 | -5,026 | -22,857 | -5,102 | -6,881 |
| Net Income Continuous | -7,336 | -5,026 | -22,857 | -5,102 | -6,881 |
| Net Income | $-7,336 | $-5,026 | $-22,857 | $-5,102 | $-6,881 |
| EPS Basic Total Ops | -0.79 | -0.54 | -3.85 | -0.97 | -1.36 |
| EPS Basic Continuous Ops | -0.79 | -0.54 | -3.84 | -0.97 | -1.36 |
| EPS Diluted Total Ops | -0.79 | -0.54 | -3.85 | -0.97 | -1.36 |
| EPS Diluted Continuous Ops | -0.79 | -0.54 | -3.84 | -0.97 | -1.36 |
| EPS Diluted Before Non-Recurring Items | -0.79 | -0.54 | N/A | N/A | N/A |
| EBITDA(a) | $-9,232 | $-9,490 | $-17,929 | $-4,338 | $-5,584 |